Servier Presents Updated Translational Data from Perioperative Study of Vorasidenib and TIBSOVO® (ivosidenib tablets) in Patients with IDH Mutant Low-Grade Glioma at ASCO 2021
BOSTON, June 7, 2021 /PRNewswire/ — Servier, a growing leader in oncology committed to bringing the promise of tomorrow to the patients we serve, today presented updated data from an ongoing perioperative study confirming robust biomarker suppression and reduced tumor cell proliferation…
Comments Off on Servier Presents Updated Translational Data from Perioperative Study of Vorasidenib and TIBSOVO® (ivosidenib tablets) in Patients with IDH Mutant Low-Grade Glioma at ASCO 2021